Clinicopathological characteristics of breast cancer patients with HER-2 low expression received neoadjuvant therapy

CONCLUSIONS: In general, further studies are needed to confirm that HER-2 low expression is a special breast cancer molecular subtype. The efficacy of neoadjuvant therapy in patients with HER-2 low expression is relatively poor, and the efficacy of neoadjuvant therapy can predict the prognosis of patients with HER-2 low expression.PMID:37669631 | DOI:10.1159/000533787

Source: Oncology - September 5, 2023 Category: Cancer & Oncology Authors: Shiyuan Zhang Xiao Yu Yuting Xiu Kun Qiao Cong Jiang Yuanxi Huang Source Type: research